Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
34 Leser
Artikel bewerten:
(0)

Global Pen Needles (Insulin, Glucagon-like peptide, Growth Hormones) Market - Analysis & Forecast to 2019

DUBLIN, November 13, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/gln9j8/pen_needles) has announced the addition of the "Pen Needles Market by Type, Needle Length, Therapy - Analysis & Global Forecast to 2019" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The pen needles market is highly competitive with a large number of players, including both big and small players, operating in this market. Needles are used by patients to deliver insulin daily to their body. Rise in the global diabetic population and the increasing need for safety injections have resulted in technological advancements in this field.

The global pen needles market is segmented on the basis of type, needle length, therapy, and region. By type, the pen needles market is categorized into standard and safety needles. The standard pen needles segment is expected to account for the largest share of the market, by type. However, the safety needles segment is expected to grow at the fastest rate in the market, by type.

On the basis of needle length, the market is divided into 4mm, 5mm, 6mm, 8mm, 10mm, and 12mm. Pen needles with 6mm length is expected to account for the largest share of the market, by needle length. However, the needles with 4mm length are expected to grow at the fastest rate in the market, by needle length.

The pen needles market, by therapy is segmented into insulin, Glucagon-like peptide (GLP), and growth hormones. Insulin therapy is the largest (2014) and fastest (2014-2019) growing market of the market, by therapy.

The key factors that are expected to spur the growth of this market are the rising global diabetic population, favorable reimbursement scenario in North America and Europe, technological advancements, and awareness campaigns and conferences to improve diabetes care and adoption market. However, poor reimbursement structure in developing countries, rising incidents of needlestick injuries (NSIs), and threats involved in reuse of pen needles are hindering the market growth.

On the basis of region, this market is classified into North America, Europe, Asia, and Rest of the World (RoW).

The global pen needles market is expected to reach $2,105 million in 2019 from $1,283 million in 2014, growing at a CAGR of 10.4%. The market is dominated by Europe, followed by North America, Asia, and Rest of the World (RoW). Asia is expected to reach leadership position in terms of the value by 2019.

Some of the major players in the global market include Becton, Dickinson and Company (U.S.), Novo Nordisk (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), HTL-Strefa S.A. (Poland), Terumo Corporation (Japan), Artsana S.p.a (Italy), Owen Mumford Ltd (U.K.), Allison Medical, Inc. (U.S.), and Ultimed, Inc. (U.S.).


Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Pen Needles Market, By Type

8 Pen Needles Market, By Length

9 Pen Needles Market, By Therapy

10 Pen Needles Market, By Geography

11 Competitive Landscape

12 Company Profiles

13 Appendix


Companies Mentioned:

  • Allison Medical, Inc.
  • Artsana S.P.A.
  • B. Braun Melsungen
  • Becton, Dickinson And Company
  • Htl-Strefa S.A.
  • Novo Nordisk A/S
  • Owen Mumford, Ltd.
  • Terumo Corporation
  • Ultimed, Inc.
  • Ypsomed Holding Ag


For more information visit http://www.researchandmarkets.com/research/gln9j8/pen_needles


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.